Background: In-hospital outcomes following decisions of withholding or withdrawing in Intensive Care Unit (ICU) patients have been previously assessed, little is known about outcomes after ICU and hospital discharge. Our objective was to report the 6-month outcomes of discharged patients who had treatment limitations in a general ICU and to identify prognostic factors of survival.
| I NT ROD UCTI ON
During the past 20 years, guidelines for the withholding (Wh) and withdrawal (Wd) of life support have been published in the United States 1 and France. 2 In 2005, a law in France has been voted for 3 (n8 2005-370 of April 22, 2005) , providing a legal framework for decisions to Wh or Wd life-sustaining treatments in critically ill patients. This law authorizes the withdrawal or withholding of life-sustaining therapies when they are 'useless, disproportionate or have no other effect than solely the artificial preservation of life'. It introduces the essential concept of futility and supports avoiding situations that may be considered as 'irrational obstinacy'. Several studies have shown that the withholding and withdrawal of life support are common practices in Europe. For instance, Ferrand et al 4 reported in 2001 that, in 113 decision to withhold or withdraw life support and that such decisions affected approximately 10% of all patients. These findings have been confirmed in more recent studies [5] [6] [7] [8] [9] and it appears that the withholding of life support in critically-ill patients does not necessarily lead to death in the ICU. Ferrand et al 4 reported an ICU discharge rate of 43% after Wh, and a recent study 6 reported an ICU discharge rate of 37% and a hospital discharge rate of 17%. Although in-hospital outcomes in ICU patients following decisions to Wh or Wd life support have been previously assessed, the outcomes in these patients several months after hospital discharge remain unknown. For this purpose, we conducted a retrospective study to assess the 6-month outcomes of patients discharged from the ICU after life-sustaining treatments were limited and to identify prognostic factors for survival.
| M ATE RI ALS AN D ME THO DS

| Study design and measurements
This study was conducted in a 15-bed ICU at the General Public Hospital of Saint-Malo, France. All patients who had been discharged from the ICU and experienced withheld lifesupport from January 1, 2009 to December 31, 2011 were included in the study. Patients with incomplete data such as comorbidities or vital status at 6 months were excluded from the study.
Withholding was defined in accordance with the French guidelines 2 edited by the French Intensive Care Society as a planned decision not to institute or optimize therapies that were otherwise warranted: endotracheal intubation, noninvasive ventilation, renal replacement therapy, increased doses of vasopressor infusions beyond a defined threshold, transfusion of blood products, antimicrobial therapy, surgery, increased fraction of inspired oxygen beyond a defined threshold, external cardiac massage and ICU readmission. Data collected for all patients were as follows: age, sex, severity of illness at admission according to the simplified acute physiological score (SAPS II) 10 and the sequential organ failure assessment score (SOFA) 11 at admission. Life expectancy was estimated using the McCabe classification 12 : class A for no disease or a nonfatal underlying disease, class B for an ultimately fatal disease (death expected in a 5-year period) and class C for a rapidly fatal disease (death expected within 1 year). Diagnoses were coded according to the International Classification of Diseases, 10th revision (ICD-10). The primary diagnosis was defined according to the major organ dysfunction and classified into 1 of 7 categories: acute respiratory failure without cardiac failure, coma including toxic causes, renal failure and metabolic disorders, acute pulmonary cardiogenic edema or shock, acute liver failure or digestive failure, surgical history or sepsis. 13 We also 
| Statistical analysis
Values are presented as the median (Inter Quartile Range) for continuous variables or number (percentages) for categorical variables. The 2 groups (survivors vs non-survivors) were compared using Student's t-test for continuous variables and a chi-square or Fisher's exact test for categorical variables. First, univariate analysis was performed for each potential factor. Factors with a P value of less than .2 in the univariate analysis were then introduced as part of a Cox proportional hazard model, excluding redundant variables associated with long-term survival. Hazard ratios (HR) and their 95% confidence intervals (CI) were estimated from the estimated parameters of the final regression model. Survival curves with a 95% confidence interval were computed using the Kaplan-Meier method. Patients were censored at 6 months. Statistical analyses were performed using the StatView statistical software version 5.0 (SAS Institute, Cary, NC, USA); P values of less than .05 were considered significant.
| RES U LTS
| Overall population
During the study period, 1483 patients were admitted to the ICU. The mortality rate was 17% (255 deaths, 1228 discharged from the ICU) during the ICU stay. Of the 1483 patients admitted, 264 had life support Wh or Wd during their ICU stay (17.8% of all patients). Among them, 119 patients (45% of this group and 9.7% of all patients discharged from the ICU) were discharged from the ICU. Five patients were excluded because of incomplete data, specifically their comorbidities (2 patients) and their vital status at 6 months (3 foreign patients). Thus, 114 patients were included in the study group. Figure 1 shows the flowchart of the selection of included study participants. All patients from whom life support was Wd died in the ICU (145 patients).
Of the 1483 patients admitted, 1219 had no treatment limitations and 110 died within 6 months (9%) after ICU discharge.
| Studied population: patients discharged from the ICU after a decision to withhold life-sustaining therapies
The baseline characteristics of the study group are shown in Table 1 . The Wh measures implemented are shown in Table 2 . A total of 328 measures were taken. The previous quality of life was the most frequently reported reason for Wh life support. Endotracheal intubation was the most frequently cited type of limitation (81 patients, 71%). Of note, NIV was withheld in 5%.
| Long-term survival analysis after ICU discharge
After ICU discharge, 67 patients for whom life-sustaining therapies were withheld were alive (58.8%), and 47 (41%) patients had died within 6 months. 
Abbreviations: COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; NYHA, New York Heart Association; SAPS, simplified acute physiologic score; SOFA, sequential organ failure assessment. Data are presented as number (%) or median (interquartile range). Totals of main comorbidities are higher than 100% because several comorbidities were reported in most cases.
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|
For the study group, the mean survival time was 124 6 72 days.
Characteristics of the patients in the survivor and nonsurvivor groups at 6 months post-hospital discharge are shown in Table 3 . Survival was significantly associated with a longer length of ICU and hospital stay, an ICU admission for acute respiratory failure, a medical history of chronic respiratory disease or chronic obstructive pulmonary disease, and a lower SAPS II score at admission. To assess the impact of life expectancy before ICU admission, we compared the Mc Cabe score of patients according to each main comorbidity (Table 4) .
The multivariate analysis identified a previous history of COPD (HR 5 2.11; IC 95% 1.02-4.36) and a longer length of hospital stay (HR 5 1.03; IC 95% 1.004-1.5) as factors associated with better survival rates (Table 3) .
3.4 | Long-term outcomes of COPD patients after ICU discharge for whom life-sustaining therapies were withheld Forty-one patients were admitted for acute respiratory failure. The mean survival duration of these patients was 144 days versus 95 days for patients with other diagnoses. Eleven of these 41 patients (26.8%) had been previously admitted to the ICU, and life support was withheld (no intubation) in the previous stays of 4 patients. We compared the survival rate of patients by previous history of COPD. As shown in Figure 2 , the survival rate at 6 months post-discharge was significantly higher for patients with a previous history of COPD. Among the 37 patients with COPD, 11 (29%) underwent invasive mechanical ventilation and 1 died. The remaining 26 COPD patients (71%) received non-invasive ventilation and 9 died within 6 months. There was no significant difference in the survival rates of patients who did or did not receive invasive ventilation (P 5 .11).
| DI S CU S S IO N
The results of our study showed that more than half of patients for whom life support was withheld in the ICU survived for at least 6 months after discharge. Among these patients with Wh decision, we also found that COPD patients had a significantly higher survival rate at 6 months postdischarge than did non-COPD patients.
Withholding life-supporting therapies does not predict certain death in the ICU. In our study, 45% of patients for whom life support was withheld in the ICU were discharged. In accordance with the findings of previous studies, we found that half of the deaths in the ICU occurred after the decisions to withhold or withdraw life support. 4, [6] [7] [8] Among those patients for whom life support was withheld, 58.8% were still alive 6 months post-discharge. Lautrette et al 15 found in 2015 a Day-30 survival of 25% after withholding life-sustaining treatment. This difference may have 2 explanations. First, they distinguished patients with withholding and with no-escalation of life-sustaining therapies for whom Day-30 survival was 65%. Second, the population of patients with chronic respiratory insufficiency was lower. Additionally, another recent French study found an ICU discharge rate of 37% and a hospital discharge rate of 17%. 6 These authors 6 reported that withholding (not withdrawing) lifesupport therapies was associated with a mortality rate of only 56% after ICU discharge as we found in our study. Of note, the 6-month survival of these patients was not assessed, however these results highlight the important survival difference between Wh and Wd, as all authors report that survival rate of Wd patients is almost nil. In our study, we found that the survival rate in these patients was significantly higher in patients with a previous history of COPD. COPD patients having survived an acute hypercapnic respiratory failure have a poor prognosis as they are highly susceptible to readmissions, life-threatening events and death, 16 with or without Wh of life-sustaining therapies.
Despite this poor prognosis, it seems better in our study than for other patients. This finding may have several explanations. First, we believe that this result arises from a better management of these patients in the COPD-treating ward, thus improving their prognosis during the post-ICU period. The death rate of COPD patients tends to stabilize, 17 probably because of a better management of COPD 18 and an increased availability of hospital and home-based non-invasive ventilation (NIV). 19 It has been shown recently that homebased NIV improves the survival of COPD patients, even among severe, stable patients. 20 This improvement was previously shown in patients with chronic respiratory failure secondary to neuromuscular or chest wall disorders. 21 A retrospective study suggested that long-term NIV could reduce the rates of hospital readmissions and acute hypercapnic respiratory failure in severe unstable COPD patients. 22 A recent multicentric randomized clinical trial of patients with persistent hypercapnia and hypoxemia showed that adding noninvasive ventilation to home oxygen therapy prolonged the time to readmission or death within 12 months. 23 Unlike other life support therapies that are only available in the ICU (such as vasopressor infusion), NIV is the only organ support Other chronic respiratory insufficiencies were as follows: idiopathic pulmonary fibrosis, n 5 3, obesity and obstructive sleep apnea, n 5 3, bronchiectasis, n 5 2, myopathy, n 5 2, amyotrophic lateral sclerosis, n 5 2.
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| therapy that is available daily at the same intensity at home, in the ward and in the ICU. Azoulay et al showed that hospital mortality rates for COPD patients admitted for acute respiratory failure were lower in comparison with other patients in both do-not-intubate group and no treatment limitation group. 24 They also showed that there was no significant decline in their quality of life at day-90, and that 56% of patients with a do-not-intubate status were alive at hospital discharge. Second, according to recent studies, invasive mechanical ventilation worsens the short-and long-term prognoses of patients with acute-on-chronic respiratory insufficiency. 25, 26 It also has been shown to be of no benefit in the most severe patients. 27, 28 As endotracheal intubation was the most frequent life-support therapies withheld, we hypothesize that the COPD patients who had withheld life-support therapy during their ICU stay still benefited from NIV in ward and ICU during the following acute hypercapnic respiratory failure. Of note, although other studies used day-30 or day-90 mortality, we decided to study 6 months mortality because of the high mortality rate expected and to avoid loss to follow-up.
Our study highlights the importance of individualization of post-ICU follow-up care to improve patient survival and to avoid new exacerbations. Furthermore, we think that the decision to withhold life-support should not lead to not readmit these patients and should not refrain from treating the COPD patients for whom life-support was withheld.
We also found in our study that the survivor patients had a significantly longer hospital stay after ICU discharge probably because of a better general condition at discharge. In addition to the retrospective nature of the study, some limitations should be acknowledged. First, we cannot exclude uncontrolled confounders or case-mix. Second, this is a single-centre study, thereby limiting its external validity. Furthermore, we only considered COPD patients in our study as it represents the major aetiology of chronic respiratory disease in our studied population. However, other chronic respiratory diseases such as idiopathic pulmonary fibrosis should be evaluated. Third, management of patients after ICU discharge should has been assessed, especially in COPD patients for whom home noninvasive ventilation prolonged the time to readmission or death within 12 months after an acute exacerbation. 23 Fourth, we cannot exclude confounding factors that have not been assessed in this specific population such as sources of stress which could be responsible for early readmission. 29 Lastly, we do not have quality of life data for surviving patients, which would have been interesting. Recent studies have emphasized that the quality of life of critically-ill survivor patients was impaired when compared to that of the general population, 30 especially after septic shock, 31 and that improving quality of life following ICU discharge is an important issue.
| C ONCL US I ON
In conclusion, our study found that a substantial proportion of patients discharged from the ICU after life-sustaining therapies were withheld survived for at least 6 months. Among them, patients with COPD appeared to have a significantly higher survival rate. These results highlight the notion that the decision to withhold life-sustaining therapies should not lead to a cessation of post-ICU follow-up care and that COPD patients with a decision to withhold endotracheal intubation may still benefit of ICU-readmission.
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